InsiderTrades.com logo
Charles A. Deignan net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Charles Deignan Biography and Net Worth

CFO of Clearside Biomedical
Mr. Deignan has served as our Chief Financial Officer since 2012. He is responsible for all financial and administrative aspects of the company including financing, business planning and analysis, investor relations, tax, accounting, treasury, human resources, and information technology. Mr. Deignan has overseen multiple partnering agreements, private financings and public equity fundraising, including Clearside’s initial public offering and subsequent completion of various equity transactions and debt facilities. From 2009 to 2011, Mr. Deignan was Vice President of Finance and Administration for Salutria Pharmaceuticals. Previously, from 1999 to 2009, Mr. Deignan served in a number of roles with AtheroGenics, Inc., a publicly held biopharmaceutical company, including as its Vice President of Finance and Administration. Prior to that, he held management positions at AAIPharma, Inc. and Schering-Plough. Mr. Deignan received his B.S. degree in Business Administration from Boston University.

What is Charles A. Deignan's net worth?

The estimated net worth of Charles A. Deignan is at least $10.51 thousand as of January 19th, 2024. Mr. Deignan owns 25,644 shares of Clearside Biomedical stock worth more than $10,514 as of April 10th. This net worth approximation does not reflect any other assets that Mr. Deignan may own. Learn More about Charles A. Deignan's net worth.

How do I contact Charles A. Deignan?

The corporate mailing address for Mr. Deignan and other Clearside Biomedical executives is 900 NORTH POINT PARKWAY SUITE 200, ALPHARETTA GA, 30005. Clearside Biomedical can also be reached via phone at (678) 270-3631 and via email at [email protected]. Learn More on Charles A. Deignan's contact information.

Has Charles A. Deignan been buying or selling shares of Clearside Biomedical?

Charles A. Deignan has not been actively trading shares of Clearside Biomedical during the last quarter. Most recently, Charles A. Deignan sold 860 shares of the business's stock in a transaction on Friday, January 19th. The shares were sold at an average price of $19.20, for a transaction totalling $16,512.00. Following the completion of the sale, the chief financial officer now directly owns 25,644 shares of the company's stock, valued at $492,364.80. Learn More on Charles A. Deignan's trading history.

Who are Clearside Biomedical's active insiders?

Clearside Biomedical's insider roster includes Richard Burke (Director), Thomas Ciulla (Insider), Charles Deignan (CFO), George Lasezkay (CEO), and Bradford Whitmore (Major Shareholder). Learn More on Clearside Biomedical's active insiders.

Charles A. Deignan Insider Trading History at Clearside Biomedical

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/19/2024Sell860$19.20$16,512.0025,644View SEC Filing Icon  
1/19/2023Sell935$22.50$21,037.5024,231View SEC Filing Icon  
1/19/2022Sell588$31.35$18,433.80View SEC Filing Icon  
9/21/2021Sell186$96.15$17,883.90View SEC Filing Icon  
6/21/2021Sell195$65.55$12,782.2521,283View SEC Filing Icon  
11/12/2019Buy500$17.10$8,550.0013,590View SEC Filing Icon  
3/15/2019Buy666$20.40$13,586.405,090View SEC Filing Icon  
3/23/2018Buy33$176.85$5,836.054,423View SEC Filing Icon  
8/14/2017Buy66$106.05$6,999.304,353View SEC Filing Icon  
See Full Table

Charles A. Deignan Buying and Selling Activity at Clearside Biomedical

This chart shows Charles A Deignan's buying and selling at Clearside Biomedical by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Clearside Biomedical Company Overview

Clearside Biomedical logo
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
Read More

Today's Range

Now: $0.41
Low: $0.41
High: $0.41

50 Day Range

MA: $1.19
Low: $0.36
High: $4.07

2 Week Range

Now: $0.41
Low: $0.37
High: $17.10

Volume

N/A

Average Volume

152,333 shs

Market Capitalization

$2.15 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.04